Idorsia Starts Phase 3 Lucerastat Study, Signs Nxera Agreement
Idorsia says it has initiated a pivotal Phase 3 study of lucerastat for Fabry disease and entered a co-development and commercialization agreement with Nxera.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Idorsia Starts Phase 3 Lucerastat Study and Signs Nxera Agreement
Idorsia initiated a pivotal Phase 3 study of lucerastat in Fabry disease and entered a co-development and commercialization agreement with Nxera.